Andrew Woolley serves as a Principal Scientist in Oncology Biomarkers at Bristol Myers Squibb, where he plays a pivotal role in advancing precision medicine through the development of innovative tissue-based research assays. With nearly a decade of experience in the biopharmaceutical industry, Andrew has honed...
Andrew Woolley serves as a Principal Scientist in Oncology Biomarkers at Bristol Myers Squibb, where he plays a pivotal role in advancing precision medicine through the development of innovative tissue-based research assays. With nearly a decade of experience in the biopharmaceutical industry, Andrew has honed his expertise in histology and digital pathology, focusing primarily on Immuno-Oncology. His work is centered on the creation and validation of novel immunohistochemistry (IHC) protocols and other tissue biomarkers, which are essential for preclinical discovery and translational research.
In his current role, Andrew is responsible for leading the spatial-analysis characterization of histological tissues, employing advanced techniques such as multiplex immunofluorescence (mIF), in situ hybridization (ISH), and spatial transcriptomics using 10x Genomics platforms. His proficiency in digital pathology image analysis, particularly with HALO AI, allows him to derive meaningful insights from complex tissue samples, ultimately supporting decisional biomarker strategies across multiple Immuno-Oncology programs at BMS.
Andrew’s passion for improving patient outcomes drives his commitment to integrating cutting-edge technologies with traditional histological methods. His skill set encompasses a wide range of techniques, including microscopy, confocal microscopy, and in vivo studies, making him a versatile asset in the field of biomedical engineering and life sciences. As he continues to push the boundaries of research, Andrew Woolley remains dedicated to the mission of enhancing therapeutic efficacy and patient care through the power of precision medicine.
